SEC Comment Letter for Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989) (OTLK) — Mar 21, 2017
Outlook Therapeutics, Inc. (OTLK) (CIK 0001649989)
Date: March 21, 2017 · CIK: 0001649989 · Accession: 0000000000-17-009304
AI Filing Summary & Sentiment
File numbers found in text: 333-216610
Letter
Mail Stop 4546 March 21, 2017 Lawrence Kenyon Chief Financial Officer Oncobiologics, Inc. 7 Clarke Drive Cranbury, NJ 08512
Re: Oncobiologics, Inc. Registration Statement on Form S-1 Filed March 10 , 2017 File No. 333-216610
Dear Mr. Kenyon :
This is to advise you that we have not reviewed and will not review your registration statement .
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at (202) 551 -5019 with any questions.
Sincerely,
/s/ Erin K. Jaskot, for
Show Raw Text
Mail Stop 4546 March 21, 2017 Lawrence Kenyon Chief Financial Officer Oncobiologics, Inc. 7 Clarke Drive Cranbury, NJ 08512 Re: Oncobiologics, Inc. Registration Statement on Form S-1 Filed March 10 , 2017 File No. 333-216610 Dear Mr. Kenyon : This is to advise you that we have not reviewed and will not review your registration statement . Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551 -5019 with any questions. Sincerely, /s/ Erin K. Jaskot, for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Yvan -Claude Pierre , Esq. Cooley LLP